Did you know that breast cancer in women is the second most common type of cancer in the US? The National Cancer Institute estimates that 232,670 American women were diagnosed with breast cancer and 40,000 died from the disease in 2014. We are excited to announce that the U.S. Food and Drug Administration granted accelerated approval to Ibrance (palbociclib) to treat advanced (metastatic) breast cancer.
In addition, Avella is proud to fulfill IBRANCE® (palbociclib) in treating patients with advanced (metastatic) breast cancer. Ibrance will be used in the treatment of postmenopausal women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer who have not yet received an endocrine-based therapy. It is to be used in combination with letrozole. Ibrance works by inhibiting molecules involved in promoting the growth of cancer cells.
The drug was approved under the FDA’s accelerated approval program which gives patients earlier access to promising new drugs while manufacturers conduct additional clinical trials. This type of approval is used for drugs intended to treat serious or life-threatening diseases and where data shows a strong likelihood of clinical benefit for patients. The approval was based on data from a study on 165 postmenopausal women with this classification of metastatic breast cancer who had not received previous treatment for the advanced disease. The study found that Ibrance stopped tumors from growing for a median of more than 20 months, about twice as long as current treatments. The drug also received a priority FDA review, which is an expedited review of drugs intended to provide a significant improvement in safety or effectiveness in the treatment of a serious condition or meet an unmet medical need. Full prescribing information can be found at www.ibrance.com.
To learn how we support cancer patients and their providers, visit avella.com/oncology. You can also learn more about oncology-focused services we offer as well as download our Oncology referral form.
How will Avella work with your Oncology patients? Once we receive the prescription, we will:
- Verify patient benefits and coordinate prior authorizations, when applicable
- If the patient has a high co-pay, our Financial Assistance Specialists will work with the patient and your office to apply the patient to any applicable co-pay assistance programs
- You will receive a confirmation regarding the status of each patient in 24-48 hours
Your dedicated Avella team will handle the rest.
- We will contact the patient to arrange delivery to their home at no additional fee
- Our clinical pharmacists are available 24/7 for patient support